Short answer
Aquestive Therapeutics, Inc. (AQST) filed an 8-K current report with the SEC on August 10, 2026 reporting Item 7.01 (Regulation FD Disclosure), Item 8.01 (Other Events). Investor presentation furnished August 10, 2026 for institutional investor and analyst meetings.
Aquestive Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 7.01 · Regulation FD Disclosure
- Investor presentation furnished August 10, 2026 for institutional investor and analyst meetings
- Exhibit 99.2 contains the substantive company updates and materials
- Disclosure may be amended or updated through subsequent filings or communications
Item 8.01 · Other Events
- Anaphylm human factors and pharmacokinetic study results support planned FDA NDA resubmission
- Potential advancement toward approval for Type 1 allergic reactions, including anaphylaxis
- Study outcomes and regulatory relevance detailed in Exhibit 99.1
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Aquestive Therapeutics, Inc. 8-K filings
Get the next AQST 8-K as it lands
Follow AQST for push alerts, or ask the research agent what this filing means.